A low-power data acquisition system for geomagnetic observatories and variometer stations

A modern geomagnetic observatory must provide data of high stability, continuity, and resolution. The INTERMAGNET network has therefore specified quantitative criteria to ensure a high quality standard of geomagnetic observatories. Here, we present a new data acquisition system which was designed to meet these criteria, in particular with respect to 1 Hz data. This system is based on a Raspberry Pi embedded PC and runs a C+ +  data acquisition software. As a result, the data acquisition system is modular, cheap, and flexible, and it can be operated in remote areas with limited power supply. In addition, the system is capable of near-real-time data transmission, using a reverse SSH tunnel to work with any network available. The system hardware was successfully tested at the Niemegk observatory for a period of 1 year and subsequently installed at the Tatuoca observatory in Brazil

Using Principal Component Analysis of Satellite and Ground Magnetic Data to Model the Equatorial Electrojet and Derive Its Tidal Composition

The intensity of the equatorial electrojet (EEJ) shows temporal and spatial variability that is not yet fully understood nor accurately modeled. Atmospheric solar tides are among the main drivers of this variability but determining different tidal components and their respective time series is challenging. It requires good temporal and spatial coverage with observations, which, previously could only be achieved by accumulating data over many years. Here, we propose a new technique for modeling the EEJ based on principal component analysis (PCA) of a hybrid ground-satellite geomagnetic data set. The proposed PCA-based model (PCEEJ) represents the observed EEJ better than the climatological EEJM-2 model, especially when there is good local time separation among the satellites involved. The amplitudes of various solar tidal modes are determined from PCEEJ based tidal equation fitting. This allows to evaluate interannual and intraannual changes of solar tidal signatures in the EEJ. On average, the obtained time series of migrating and nonmigrating tides agree with the average climatology available from earlier work. A comparison of tidal signatures in the EEJ with tides derived from neutral atmosphere temperature observations show a remarkable correlation for nonmigrating tides such as DE3, DE2, DE4, and SW4. The results indicate that it is possible to obtain a meaningful EEJ spectrum related to solar tides for a relatively short time interval of 70 days

On the characterization of tidal ocean-dynamo signals in coastal magnetic observatories

Periodic tidal ocean currents induce electric currents and, therefore, magnetic field signals that are observable using spaceborne and ground-based observation techniques. In theory, the signals can be used to monitor oceanic temperature and salinity variations. Tidal magnetic field amplitudes and phases have been extracted from magnetometer measurements in the past. However, due to uncertainties caused by a plentitude of influencing factors, the shape and temporal variation of these signals are only known to a limited extent. This study uses past extraction methods to characterize seasonal variations and long-term trends in the ten year magnetometer time series of three coastal island observatories. First, we assess data processing procedures used to prepare ground-based magnetometer observations for tidal ocean dynamo signal extraction to demonstrate that existing approaches, i.e., subtraction of core field models or first-order differencing, are unable to reliably remove low-frequency contributions. We hence propose low-frequency filtering using smoothing splines and demonstrate the advantages over the existing approaches. Second, we determine signal and side peak magnitudes of the M2 tide induced magnetic field signal by spectral analysis of the processed data. We find evidence for seasonal magnetic field signal variations of up to 25% from the annual mean. Third, to characterize the long-term behavior of tidal ocean dynamo signal amplitudes and phases, we apply different signal extraction techniques to identify tidal ocean-dynamo signal amplitudes and phases in sub-series of the ten-year time series with incrementally increasing lengths. The analyses support three main findings: (1) trends cause signal amplitude changes of up to ~1 nT and phase changes are in the order of O(10°) within the observation period; (2) at least four years of data are needed to obtain reliable amplitude and phase values with the extraction methods used and (3) signal phases are a less dependent on the chosen extraction method than signal amplitudes

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.

In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1-21; 28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine). The intent-to-treat population comprised 254 patients (lenalidomide, n = 170; IC, n = 84). Subgroup analyses of PFS favoured lenalidomide over IC across most characteristics, including risk factors, such as high MCL International Prognostic Index score, age ≥65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high tumour burden, and refractoriness to last prior therapy. By multivariate Cox regression analysis, factors associated with significantly longer PFS (other than lenalidomide treatment) included normal LDH levels (P < 0·001), nonbulky disease (P = 0·045), <3 prior antilymphoma treatments (P = 0·005), and ≥6 months since last prior treatment (P = 0·032). Overall, lenalidomide improved PFS versus single-agent IC therapy in patients with relapsed/refractory MCL, irrespective of many demographic factors, disease characteristics and prior treatment history

Altitude dependence of nightside Martian suprathermal electron depletions as revealed by MAVEN observations

The MAVEN (Mars Atmosphere and Volatile EvolutioN) spacecraft is providing new detailed observations of the Martian ionosphere thanks to its unique orbital coverage and instrument suite. During most periapsis passages on the nightside ionosphere suprathermal electron depletions were detected. A simple criterion was implemented to identify the 1742 depletions observed from 16 November 2014 to 28 February 2015. A statistical analysis reveals that the main ion and electron populations within the depletions are surprisingly constant in time and altitude. Absorption by CO2 is the main loss process for suprathermal electrons, and electrons that strongly peaked around 6 eV are resulting from this interaction. The observation of depletions appears however highly dependent on altitude. Depletions are mainly located above strong crustal magnetic sources above 170 km, whereas the depletions observed for the first time below 170 km are globally scattered onto the Martian surface with no particular dependence on crustal fields

Plain language summary of the TRANSFORM study primary analysis results:liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen

What is this summary about?People diagnosed with a disease called large B-cell lymphoma (LBCL) may experience return, or early relapse, of their disease within the first year after receiving and responding to their first (first-line) treatment regimen. Others may have primary refractory disease, meaning that the disease either did not respond to first-line treatment at all or only responded for a very brief period. Second (second-line) treatment includes immunotherapy followed by high-dose chemotherapy and ASCT, which has the potential to cure LBCL. However, if the disease does not respond to immunotherapy, people cannot receive ASCT, and less than 30% of people are cured.Therefore, new second-line treatment options are required, such as CAR T cell therapy, which uses a person's own genetically engineered lymphocytes, also called T cells, to fight their lymphoma. In this article, we summarize the key results of the phase 3 TRANSFORM clinical study that tested if liso-cel, a CAR T cell treatment, can safely and effectively be used as a second-line treatment for people with early relapsed or primary refractory (relapsed/refractory) LBCL.A total of 184 adults with relapsed/refractory LBCL who were able to receive ASCT were randomly treated with either liso-cel or standard of care (SOC) as second-line treatment. SOC included immunochemotherapy followed by high-dose chemotherapy and ASCT.What were the key takeaways?Almost all (97%) people in the liso-cel group completed treatment, whereas 53% of people in the SOC group did not complete treatment, mostly due to their disease not responding or relapsing, and therefore they were not able to receive ASCT. People who received liso-cel as a second-line treatment lived longer without the occurrence of an unfavorable medical event or worsening of the disease and had a better response to treatment than those who received SOC as second-line treatment. People who received liso-cel reported side effects that researchers considered to be manageable, and that were known to occur with CAR T cell treatment.What were the main conclusions reported by the researchers?Results from the TRANSFORM study support the use of liso-cel as a more effective second-line treatment compared with SOC that is safe for people with relapsed/refractory LBCL

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)

Background The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated. We report the results of a trial which evaluates the role of rituximab combined with ACVBP (R-ACVBP) in these patients. Patients and methods Untreated patients younger than 66 years with stage I or II DLBCL and no adverse prognostic factors of the age-adjusted International Prognostic Index were randomly assigned to receive three cycles of ACVBP plus sequential consolidation with or without the addition of four infusions of rituximab. Results A total of 223 patients were randomly allocated to the study, 110 in the R-ACVBP group and 113 in the ACVBP group. After a median follow-up of 43 months, our 3-year estimate of event-free survival was 93% in the R-ACVBP group and 82% in the ACVBP group (P = 0.0487). Three-year estimate of progression-free survival was increased in the R-ACVBP group (95% versus 83%, P = 0.0205). Overall survival did not differ between the two groups with a 3-year estimates of 98% and 97%, respectively (P = 0.686). Conclusion In young patients with low-risk localized DLBCL, rituximab combined with three cycles of ACVBP plus consolidation is significantly superior to ACVBP plus consolidation alon

Gene expression in fungi

This contribution is based on the four presentations made at the Special Interest Group (SIG) meeting titled Gene Expression in Fungi held during IMC9 in Edinburgh. This overview is independent from other articles published or that will be published by each speaker. In the SIG meeting, basic principles of in vivo animal models for virulence studies were discussed. Infection associated genes of Candida albicans and fungal adaptation to the host was summarized. Azole susceptibility was evaluated as a combined result of several changes in expression of pertinent genes. Gene transfer in fungi, resulting in fungal evolution and gene adaptation to environmental factors, was reported

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have high relapse rates following standard therapy. Despite use of consolidative stem cell transplant (SCT) following frontline therapy, there remains no consensus on its utility. The double-blind randomized phase 3 ECHELON-2 study (#NCT01777152; clinicaltrials.gov) demonstrated improved progression-free survival (PFS) and overall survival with frontline brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP). Herein, we conducted an exploratory subgroups analysis of the impact of consolidative SCT on PFS in patients with previously untreated CD30+ PTCL (ALK- anaplastic large cell lymphoma [ALCL] and non-ALCL) who were in complete response (CR) after frontline treatment with A+CHP or cyclophosphamide, doxorubicin, vincristine, and prednisone. Median PFS follow-up was 47.57 months. The PFS hazard ratio was 0.36, equating to a 64% reduction in the risk of a PFS event in patients who underwent SCT. The median PFS in patients who underwent SCT was not reached, vs 55.66 months in patients who did not undergo SCT. PFS results favored the use of SCT in both ALK- ALCL and non-ALCL subgroups. These data support the consideration of consolidative SCT in patients with CD30+PTCL who achieve CR following treatment with A+CHP

A demographic and epidemiological study of a Mexican chiropractic college public clinic

<p>Abstract</p> <p>Background</p> <p>Descriptive studies of chiropractic patients are not new, several have been performed in the U.S., Australia, Canada, and Europe. None have been performed in a Latin American country. The purpose of this study is to describe the patients who visited a Mexican chiropractic college public clinic with respect to demographics and clinical characteristics.</p> <p>Methods</p> <p>This study was reviewed and approved by the IRB of Parker College of Chiropractic and the Universidad Estatal del Valle de Ecatepec (UNEVE). Five hundred patient files from the UNEVE public clinic from May 2005 to May 2007 were selected from an approximate total number of 3,700. Information was collected for demographics, chief complaints, associated complaints, and previous care sought.</p> <p>Results</p> <p>The sample comprised 306 (61.2%) female. Most files (44.2%) were in the age range of 40–59 years (mean of 43.4 years). The most frequent complaints were lumbar pain (29.2%) and extremity pain (28.0%), most commonly the knee. Most (62.0%) described their complaints as greater than one year. Trauma (46.6%) was indicated as the initial cause. Mean VAS score was 6.26/10 with 20% rated at 8/10.</p> <p>Conclusion</p> <p>Demographic results compared closer to studies conducted with private clinicians (females within the ages of 40–59). The primary complaint and duration was similar to previous studies (low back pain and chronic), except in this population the cause was usually initiated by trauma. The most striking features were the higher number of extremity complaints and the marked increased level of VAS score (20% rated as 8/10).</p